Advanced Therapeutics in Rheumatoid Arthritis (RA)
Recruiting · NCT03976245 · Interventional (participants receive a specific treatment) · Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- patients with RA who meet criteria for obtaining an advanced therapeutic through usual care
- active RA with 5 or more swollen joints
- seropositive
- presence of erosions
- failure of methotrexate and hydroxychloroquine and sulfasalazine
- failure of Leflunomide
- \> or equal to 18 years
- able to provide consent
- able to attend usual follow up visits
Exclusion criteria
- no contraindication to etanercept or tofacitinib
- active serious infection
- active Tuberculosis
- multiple sclerosis
- current cancer
- lymphoma ever
- previous use of an advanced therapeutic (biologic or JAK kinase inhibitor)
- less than 18 years of age
- unable to provide consent
Where it is running
1 location listed.
- Rheumatology Clinic, St. Joseph's Health Care - London, Ontario, Canada